Spark Biopharma Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
30
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$21.4M
- Investors
-
29
Spark Biopharma General Information
Description
Operator of a drug development company intended to focus on the development of small-molecule therapeutics through the integration of biology. The company's therapeutic drug is produced from the compound library and bio probe developed with domestic original technology, it is developing new drug candidates using image-based screening technology with a fluorescent skeleton probe and target protein identification technology, enabling the medical industry to obtain therapeutic candidates for cardiovascular and other metabolic diseases.
Contact Information
Website
sparkbiopharma.comCorporate Office
- 7th Floor, 134, Gwanak -ro, Gwanak
- Seoul, 08791
- South Korea
Corporate Office
- 7th Floor, 134, Gwanak -ro, Gwanak
- Seoul, 08791
- South Korea
Spark Biopharma Timeline
Spark Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 11-May-2026 | $21.4M | Completed | Clinical Trials - Phase 2 | ||
| 8. Secondary Transaction - Private | 01-Apr-2023 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC (Series C) | 04-Apr-2022 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC | 25-Nov-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series B) | 26-Aug-2019 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series A) | 01-Jan-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 2. Accelerator/Incubator | 01-Nov-2017 | $882K | $882K | Completed | Clinical Trials - Phase 1 | |
| 1. Seed Round | 01-Jan-2017 | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Spark Biopharma Comparisons
Industry
Financing
Details
Spark Biopharma Competitors (41)
One of Spark Biopharma’s 41 competitors is BenevolentAI, a Formerly PE-Backed company based in Luxembourg, Luxembourg.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BenevolentAI | Formerly PE-Backed | Luxembourg, Luxembourg | ||||
| X-37 | Venture Capital-Backed | South San Francisco, CA | ||||
| Exscientia | Formerly VC-backed | Oxford, United Kingdom | ||||
| NeoX Biotech | Venture Capital-Backed | Beijing, China | ||||
| Cyrus Biotechnology | Venture Capital-Backed | Seattle, WA |
Spark Biopharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Spark Biopharma Patents
Spark Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026182595-A1 | Pyridine carboxamide derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating disease, containing same as active ingredient | Pending | 28-Feb-2025 | ||
| WO-2026169078-A1 | Aminopyridine derivative, preparation method therefor, and pharmaceutical composition for preventing or treating diseases containing same as active ingredient | Pending | 06-Feb-2025 | ||
| WO-2026146787-A1 | Rational design strategy for low-molecular-weight protein secondary structure mimetics and manufacturing method therefor | Pending | 03-Jan-2025 | ||
| WO-2026127671-A1 | Heterocyclic derivative and use thereof | Pending | 12-Dec-2024 | ||
| WO-2026005544-A1 | Stress granule formation promoter and broad-spectrum antiviral composition comprising same | Pending | 28-Jun-2024 |
Spark Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Spark Biopharma Investors (29)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AOA Capital Partners (Korea) | Venture Capital | Minority | ||
| Emford Equity Partners | Venture Capital | Minority | ||
| Flexus Partners | Venture Capital | Minority | ||
| Industrial Bank of Korea | PE/Buyout | Minority | ||
| J-Bio Investment Partnership | Venture Capital | Minority |
Spark Biopharma FAQs
-
When was Spark Biopharma founded?
Spark Biopharma was founded in 2016.
-
Where is Spark Biopharma headquartered?
Spark Biopharma is headquartered in Seoul, South Korea.
-
What is the size of Spark Biopharma?
Spark Biopharma has 30 total employees.
-
What industry is Spark Biopharma in?
Spark Biopharma’s primary industry is Other Healthcare Technology Systems.
-
Is Spark Biopharma a private or public company?
Spark Biopharma is a Private company.
-
What is Spark Biopharma’s current revenue?
The current revenue for Spark Biopharma is .
-
How much funding has Spark Biopharma raised over time?
Spark Biopharma has raised $70.2M.
-
Who are Spark Biopharma’s investors?
AOA Capital Partners (Korea), Emford Equity Partners, Flexus Partners, Industrial Bank of Korea, and J-Bio Investment Partnership are 5 of 29 investors who have invested in Spark Biopharma.
-
Who are Spark Biopharma’s competitors?
BenevolentAI, X-37, Exscientia, NeoX Biotech, and Cyrus Biotechnology are some of the 41 competitors of Spark Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
